Following a stock split, Remedium Lifecare wins an order deal for Rs. 169 crore from a pharmaceutical company based in the United Arab Emirates
Remedium Lifecare is a small-cap business in the commercial services sector. Today, the stock opened higher on the BSE at Rs 139 per share. In the morning session, it was trading at Rs 134.05 per share, with an upside gap of 2.06%. A purchasing frenzy for the shares was triggered by an export order worth Rs. 69 crore that the business obtained from PHARMYKA GENERAL TRADING LLC, a pharmaceutical company situated in the United Arab Emirates.
“Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the company has received an export order of rupees one hundred nine crore (Rs. 69 crore) from PHARMYKA GENERAL TRADING LLC, a pharmaceutical company situated in UAE,” stated Remedium Lifecare in a regulatory filing.
The order(s) or contract(s) for the delivery of pharmaceutical chemicals will be completed between April 2024 and March 2025.
The Remedium Lifecare Board of Directors has notified the stock exchanges that a meeting is planned for Thursday, March 7, 2024, among other things, to discuss the purchase of a manufacturing plant that produces pharmaceutical industry intermediates close to Hyderabad.
As a result of the subdivision and stock split that reduced the face value of the equity shares from Rs. 5/-each to Rs. 1/-each, we would like to notify you that Remedium Lifecare Limited has obtained a NEW ISIN from CDSL and NSDL. In a regulatory filing on February 19, the business said, “Please take note that the company’s new ISIN is INE549S01036 and the subdivision/stock split of equity shares will take effect under the new ISIN.”
Remedium Lifecare Ltd., which is listed on the BSE, was formerly known as Roxy Exports Limited. The company offers one of the biggest portfolios of intermediates and active pharmaceutical ingredients (APIs).
